| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | John Anthony Hardy | Q6237755 |
| Jeffrey L. Cummings | Q6175920 | ||
| P2093 | author name string | Joel Raskin | |
| Robert A Dean | |||
| Kory Schuh | |||
| P2860 | cites work | TREM2 Variants in Alzheimer's Disease | Q22250873 |
| A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline | Q22251083 | ||
| Tau pathology in Alzheimer disease and other tauopathies | Q22252520 | ||
| Alzheimer's disease | Q55880664 | ||
| TREM2: a new risk factor for Alzheimer's disease | Q85949910 | ||
| Polymorphism of the OLR1 3'UTR potential microRNA binding site and risk of Alzheimer's disease: a meta-analysis | Q86265775 | ||
| Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 | ||
| Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease | Q24612662 | ||
| Biological markers of amyloid beta-related mechanisms in Alzheimer's disease | Q24622136 | ||
| Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory | Q24645499 | ||
| Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts | Q24675729 | ||
| Mechanisms of protein seeding in neurodegenerative diseases | Q26994962 | ||
| APP processing in Alzheimer's disease | Q27694738 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| The brain's default network: anatomy, function, and relevance to disease | Q27860961 | ||
| Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide | Q28131750 | ||
| Trans-synaptic spread of tau pathology in vivo | Q28732288 | ||
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective | Q29614702 | ||
| Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease | Q29614879 | ||
| An energy budget for signaling in the grey matter of the brain | Q29616192 | ||
| Decreased clearance of CNS beta-amyloid in Alzheimer's disease | Q29616534 | ||
| Amyloid precursor protein trafficking, processing, and function | Q29617429 | ||
| Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI | Q29619152 | ||
| Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers | Q29620245 | ||
| Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity | Q30493579 | ||
| Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network | Q30498362 | ||
| Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. | Q30984127 | ||
| Network analysis of intrinsic functional brain connectivity in Alzheimer's disease | Q33347142 | ||
| Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment | Q33511724 | ||
| Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. | Q33652639 | ||
| Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease | Q33782706 | ||
| In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease | Q33855136 | ||
| Midlife predictors of Alzheimer's disease | Q33956934 | ||
| Threshold-independent meta-analysis of Alzheimer's disease transcriptomes shows progressive changes in hippocampal functions, epigenetics and microRNA regulation | Q34108664 | ||
| 2012 Alzheimer's disease facts and figures | Q34260109 | ||
| MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients | Q34284143 | ||
| Alzheimer's disease risk genes and mechanisms of disease pathogenesis | Q34425904 | ||
| Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways | Q34468169 | ||
| Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease | Q34471227 | ||
| Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons | Q34590202 | ||
| The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update | Q34603491 | ||
| Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? | Q48130941 | ||
| Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses | Q48130989 | ||
| Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. | Q48182788 | ||
| Altered functional connectivity in early Alzheimer's disease: a resting-state fMRI study | Q48354897 | ||
| Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study | Q48417159 | ||
| Lessons from a failed γ-secretase Alzheimer trial | Q48449453 | ||
| The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease | Q48536651 | ||
| Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein | Q48634030 | ||
| Altered effective connectivity patterns of the default mode network in Alzheimer's disease: an fMRI study. | Q48676053 | ||
| Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment | Q48694961 | ||
| Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain | Q48710955 | ||
| Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease | Q48912229 | ||
| Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. | Q50869517 | ||
| Revising the definition of Alzheimer's disease: a new lexicon. | Q53313597 | ||
| National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease | Q34635272 | ||
| Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology | Q34738708 | ||
| Structural characterization of a soluble amyloid beta-peptide oligomer. | Q34944603 | ||
| Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure | Q35171526 | ||
| Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging | Q35204334 | ||
| Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease | Q35223831 | ||
| Purified and synthetic Alzheimer's amyloid beta (Aβ) prions | Q36079533 | ||
| Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? | Q36513243 | ||
| Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes | Q36691131 | ||
| The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals | Q37090083 | ||
| A meta-analysis of hippocampal atrophy rates in Alzheimer's disease | Q37112259 | ||
| Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. | Q37118134 | ||
| Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load | Q37158584 | ||
| Structure-neurotoxicity relationships of amyloid beta-protein oligomers | Q37329557 | ||
| Amyloid deposition is associated with impaired default network function in older persons without dementia | Q37335603 | ||
| Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. | Q37366280 | ||
| FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease | Q37415324 | ||
| Synaptic degeneration in Alzheimer's disease | Q37458270 | ||
| Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. | Q37532084 | ||
| MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects | Q37596385 | ||
| Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease | Q37668534 | ||
| Reactive astrocytes give neurons less support: implications for Alzheimer's disease | Q37807163 | ||
| Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease | Q37824813 | ||
| Amyloid precursor protein processing and Alzheimer's disease | Q37860317 | ||
| Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature | Q37982377 | ||
| Neurotoxicity of amyloid β-protein: synaptic and network dysfunction | Q38023860 | ||
| Genetic insights in Alzheimer's disease | Q38067204 | ||
| The metabolism hypothesis of Alzheimer's disease: from the concept of central insulin resistance and associated consequences to insulin therapy | Q38352298 | ||
| Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies | Q38841875 | ||
| Structural MRI changes detectable up to ten years before clinical Alzheimer's disease | Q39725773 | ||
| Deficits in the miRNA-34a-regulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer's disease (AD); an update | Q40781085 | ||
| Metabolic Mapping of Functional Activity in the Hypothalamo-Neurohypophysial System of the Rat | Q41710644 | ||
| Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease | Q41945324 | ||
| Frequency of stages of Alzheimer-related lesions in different age categories | Q42445469 | ||
| A phase 3 trial of semagacestat for treatment of Alzheimer's disease | Q42710153 | ||
| Variant TREM2 as risk factor for Alzheimer's disease | Q43457925 | ||
| Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease | Q44191043 | ||
| Circulating miRNAs as potential biomarkers in Alzheimer's disease | Q44261737 | ||
| Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons | Q44671684 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| biomarker | Q864574 | ||
| cognitive disorder | Q3065932 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 712-722 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Current Alzheimer Research | Q5195031 |
| P1476 | title | Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions | |
| P478 | volume | 12 |
| Q60530541 | Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis |
| Q41609863 | An integrated proteomics approach shows synaptic plasticity changes in an APP/PS1 Alzheimer's mouse model |
| Q89964362 | Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review |
| Q88682277 | Cannabinoid signalling in embryonic and adult neurogenesis: possible implications for psychiatric and neurological disorders |
| Q92513138 | Cell Type Specific Expression of Toll-Like Receptors in Human Brains and Implications in Alzheimer's Disease |
| Q92970138 | Chemokines in Alzheimer's Disease: New Insights Into Prokineticins, Chemokine-Like Proteins |
| Q40221089 | Circulating inflammatory biomarkers in relation to brain structural measurements in a non-demented elderly population |
| Q51759414 | Deuterated polyunsaturated fatty acids reduce brain lipid peroxidation and hippocampal amyloid β-peptide levels, without discernable behavioral effects in an APP/PS1 mutant transgenic mouse model of Alzheimer's disease. |
| Q33586027 | Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease |
| Q50535417 | Downregulated serum miR-223 servers as biomarker in Alzheimer's disease. |
| Q39022532 | Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends |
| Q37489106 | Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease |
| Q91967831 | Electroacupuncture attenuates cognition impairment via anti-neuroinflammation in an Alzheimer's disease animal model |
| Q38827962 | Five common clinical presentations in the elderly: An anatomical review |
| Q47200597 | Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to. |
| Q30489520 | Graph analysis of structural brain networks in Alzheimer's disease: beyond small world properties. |
| Q54192569 | Hypertension impairs neurovascular coupling and promotes microvascular injury: role in exacerbation of Alzheimer's disease. |
| Q37634707 | Improvements in Orientation and Balancing Abilities in Response to One Month of Intensive Slackline-Training. A Randomized Controlled Feasibility Study |
| Q88993117 | In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease |
| Q55307217 | Influence of APOE and RNF219 on Behavioral and Cognitive Features of Female Patients Affected by Mild Cognitive Impairment or Alzheimer's Disease. |
| Q47370188 | Involvement of Astrocytes in Alzheimer's Disease from a Neuroinflammatory and Oxidative Stress Perspective |
| Q37562875 | Magnetic Resonance Volumetry: Prediction of Subjective Memory Complaints and Mild Cognitive Impairment, and Associations with Genetic and Cardiovascular Risk Factors |
| Q93229357 | Neuronal Aβ42 is enriched in small vesicles at the presynaptic side of synapses |
| Q41318515 | On the path to 2025: understanding the Alzheimer's disease continuum |
| Q37490329 | Parkin Deficiency Reduces Hippocampal Glutamatergic Neurotransmission by Impairing AMPA Receptor Endocytosis |
| Q36753680 | Precision Medicine: Clarity for the Complexity of Dementia. |
| Q89287870 | Resveratrol Induces Brain Resilience Against Alzheimer Neurodegeneration Through Proteostasis Enhancement |
| Q47821988 | Resveratrol, pterostilbene, and dementia. |
| Q48216365 | Short-Term Fructose Feeding Induces Inflammation and Oxidative Stress in the Hippocampus of Young and Adult Rats |
| Q41962941 | Synergistic stress exacerbation in hippocampal neurons: Evidence favoring the dual-hit hypothesis of neurodegeneration. |
| Q39365272 | Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases |
| Q50533053 | Three-dimensional analysis of synapses in the transentorhinal cortex of Alzheimer's disease patients. |
Search more.